Ruxotemitide
Also known as: LTX-109, Ruxotemitide
Source Ruxotemitide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Ruxotemitide (LTX-109) is a synthetic cationic peptidomimetic developed by Lytone Pharma (originally Epitarget/Lytix Biopharma) for the topical treatment of bacterial skin infections, including impetigo and nasal decolonization of Staphylococcus aureus (including MRSA). It exhibits broad-spectrum antimicrobial activity through direct membrane disruption and innate immune modulation.
Mechanism of Action
Ruxotemitide (LTX-109) is a synthetic antimicrobial peptidomimetic that acts as a membrane-disrupting agent with direct bactericidal activity and also stimulates innate immune responses via TLR2 activation, disrupting bacterial cell membranes and modulating local immune defense.
Routes of Administration
Goals & Uses
- Innate immune modulationImmunologyLow
- Treatment of skin and soft tissue infections (SSTIs)Antibacterial / DermatologyLow
- Treatment of impetigoDermatology / Anti InfectiveModerate
- Nasal decolonization of MRSAAntibacterial / Infection PreventionModerate
Contraindications
- Application to open wounds or mucous membranes not indicatedAdministration SafetyModerate
- Known hypersensitivity to ruxotemitide or excipientsAllergyHigh
Adverse Effects
- Contact dermatitisDermatologicalUncommon
- Application site painLocalCommon
- Application site irritationLocal/dermatologicalCommon
- Nasal discomfortLocal/mucosalCommon
Drug Interactions
- Other topical antimicrobials (e.g., mupirocin)Low
Population Constraints
- Immunocompromised patientsImmunologicRelative
- Pregnant womenReproductiveRelative
- Pediatric patients (<2 years)AgeRelative
Regulatory Status
- European UnionInvestigationalClinical trials conducted in Europe; no EMA approval as of knowledge cutoff.
- United StatesInvestigationalFDA QIDP and Fast Track designation granted for impetigo; not yet approved. Phase 2/3 studies completed.
- United KingdomInvestigationalNo MHRA approval; investigational status.
Ruxotemitide has received Qualified Infectious Disease Product (QIDP) designation and Fast Track designation from the FDA for treatment of impetigo. It is not yet approved in any jurisdiction. Phase 2/3 clinical trials have been conducted for impetigo and nasal MRSA decolonization.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Ruxotemitide?
Ruxotemitide (LTX-109) is a synthetic cationic peptidomimetic developed by Lytone Pharma (originally Epitarget/Lytix Biopharma) for the topical treatment of bacterial skin infections, including impetigo and nasal decolonization of Staphylococcus aureus (including MRSA). It exhibits broad-spectrum antimicrobial activity through direct membrane disruption and innate immune modulation.
What is Ruxotemitide used for?
Ruxotemitide is educationally associated with: Innate immune modulation, Treatment of skin and soft tissue infections (SSTIs), Treatment of impetigo, Nasal decolonization of MRSA. Educational only — not medical advice.
How is Ruxotemitide administered?
Recorded routes of administration: Nasal, Topical.
What are the potential side effects of Ruxotemitide?
Reported adverse effects include: Contact dermatitis, Application site pain, Application site irritation, Nasal discomfort. This list is not exhaustive — consult a qualified clinician.
Who should avoid Ruxotemitide?
Recorded contraindications: Application to open wounds or mucous membranes not indicated, Known hypersensitivity to ruxotemitide or excipients. Consult a qualified clinician before use.